Also known as: Arsenic Sesquioxide Arsenic Oxidearsenous Trioxide
Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR alpha.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Arsenic trioxide is the active ingredient of these drugs:
Australia Estonia New Zealand
Austria Brazil Canada Cyprus Estonia
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):